Roman Butler Fullerton & Co’s Edwards Lifesciences EW Stock Holding History

Roman Butler Fullerton & Co’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,220	Closed	-$203K	–	187
2023 Q2	$203K	Sell	2,220 -300	-12%	-$26.1K	0.09%	183
2023 Q1	$221K	Buy	+2,520	New	+$198K	0.11%	177
2022 Q4	–	Sell	-2,520	Closed	-$207K	–	192
2022 Q3	$207K	Hold	2,520	–	–	0.13%	167
2022 Q2	$251K	Hold	2,520	–	–	0.14%	161
2022 Q1	$297K	Hold	2,520	–	–	0.14%	160
2021 Q4	$326K	Hold	2,520	–	–	0.14%	146
2021 Q3	$280K	Hold	2,520	–	–	0.13%	160
2021 Q2	$261K	Hold	2,520	–	–	0.13%	162
2021 Q1	$222K	Hold	2,520	–	–	0.11%	183
2020 Q4	$230K	Hold	2,520	–	–	0.14%	159
2020 Q3	$201K	Buy	+2,520	New	+$197K	0.13%	153
2020 Q1	–	Sell	-3,180	Closed	-$247K	–	145
2019 Q4	$247K	Buy	+3,180	New	+$248K	0.16%	148

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Roman Butler Fullerton & Co's EW Position: Q3 2023 in Review

Roman Butler Fullerton & Co sold out of Edwards Lifesciences (EW) in Q3 2023, closing a stake of 2,220 shares — an estimated $203K sold.

Roman Butler Fullerton & Co first reported a position in EW in Q4 2019 and held it in 12 quarters. The position peaked at $326K in Q4 2021. 1,220 funds tracked by Wall St. Rank hold EW as of Q3 2023.

Roman Butler Fullerton & Co reported no remaining Edwards Lifesciences position as of Q3 2023 after selling out during the quarter.
Roman Butler Fullerton & Co sold 2,220 Edwards Lifesciences shares in Q3 2023, an estimated $203K.
Roman Butler Fullerton & Co first reported a position in Edwards Lifesciences in Q4 2019 and held it in 12 quarters.
Roman Butler Fullerton & Co's Edwards Lifesciences position peaked at $326K in Q4 2021.
1,220 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2023.

Based on Roman Butler Fullerton & Co's 13F filing for Q3 2023, filed 18 Oct 2023.